TABLE 1.

Characteristics of the patients and SARS‐Cov‐2 vaccine data

Patient	Sex, age (years)	LT				Prior SARS‐CoV‐2 vaccines	Antibody levels after complete vaccination (BAU/ml)	MMF discontinuation—fourth injection (days)	Liver blood test before MMF discontinuation (AST/ALT; UI/L)	Fourth injection—antibody determination (days)	Antibody levels (BAU/ml)	Liver blood test after vaccination (AST/ALT; UI/L)
Patient	Sex, age (years)	Delay (months)	Primary indication	Medical history of liver graft rejection	Tacrolimus concentration (μg/L)	Prior SARS‐CoV‐2 vaccines	Antibody levels after complete vaccination (BAU/ml)	MMF discontinuation—fourth injection (days)	Liver blood test before MMF discontinuation (AST/ALT; UI/L)	Fourth injection—antibody determination (days)	Antibody levels (BAU/ml)	Liver blood test after vaccination (AST/ALT; UI/L)
1	Female, 53	27	HCC	No	4,2	BNT162b2 ^a ×3	0,4	16	18/8	33	451	18/9
2	Male, 68	38	HCC	No	6,5	BNT162b2 ^a ×3	7,1	34	12/10	25	669	17/15
3	Female, 58	123	HCC	No	2,8	BNT162b2 ^a ×3	4,4	7	14/10	31	3000	13/9
4	Male, 53	52	Alcohol‐associated cirrhosis	No	9,9	BNT162b2 ^a ×3	0	29	16/24		1120	16/24
5	Male, 68	141	HCC	Yes (2012)	4,9	BNT162b2 ^a ×4	237	31	24/29	16	2080	38/45
6	Male, 57	38	Alcohol‐associated cirrhosis	Yes (2018)	4,1	mRNA ^b ×2 + ChAdOx1‐S ×1	29,5	19	13/27	35	2000	15/12
7	Female, 67	27	Alcohol‐associated cirrhosis	No	9,1	BNT162b2 ^a ×3	0,4	24	24/35	16	166	26/46
8	Female, 57	214	Transthyretin amyloidosis	No	7,9	BNT162b2 ^a ×3	16,9	29	23/29	14	2080	31/39
9	Male, 71	19	HCC	No	2,2	mRNA ^b ×2 + BNT162b2 ×1	132,8	32	8/8	15	2500	11/12
10	Male, 68	15	HCC	No	6,5	BNT162b2 ^a ×3	1,7	33	15/12	14	304	13/12

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BAU, binding antibody units; ChAdOx1‐S, Vaxzevria AstraZeneca; HCC, hepatocellular carcinoma; MMF, mycophenolate‐mofetil.

^{^a}

Pfizer‐BioNTech BNT162b2.

^{^b}

mRNA‐1273.